Celu­lar­i­ty teams up with Aus­tralian biotech to de­vel­op CAR T-cell ther­a­py; For­mer Kin­nate CEO Stephen Kaldor reels in $50M for new biotech

Imu­gene and Celu­lar­i­ty have an­nounced a part­ner­ship to de­vel­op a sol­id tu­mor treat­ment, the two com­pa­nies an­nounced Wednes­day.

The col­lab­o­ra­tion will ex­plore the use of Imu­gene’s CF33-CD19, an on­colyt­ic virus, and Celu­lar­i­ty’s CAR T-cell ther­a­py CD19. Stud­ies of in vit­ro and in vi­vo mod­els will start this year.

Celu­lar­i­ty’s CD19 has shown T cell growth while killing tu­mor cells in vi­vo, and sci­en­tists be­lieve that when com­bined with CF33-CD19, the ther­a­py could im­prove out­comes for pa­tients with sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER